ADAMA Reports Financial Results for Third Quarter and First Nine Months of 2026

ADAMA Ltd. (SZSE: 000553) has reported its financial results for the third quarter and the first nine months of 2026, citing significant market headwinds. The company reported a 4% decline in quarterly sales to $897 million, attributed largely to difficult weather conditions in Europe, including record heat and drought, as well as persistent pricing pressure on off-patent agricultural products.

Key Financial Performance

• Q3 2026 Sales: $897 million, down 4% year-over-year.
• Q3 2026 Adjusted EBITDA: $93 million, a 22% decline compared to Q3 2025.
• Q3 2026 Reported Net Loss: $115 million, compared to a $48 million loss in the same period last year.
• 9M 2026 Sales: $2,997 million, a 1% decrease year-over-year.

Operational Highlights

CEO Gaël Hili noted that while market conditions remain challenging, the company is continuing to advance its strategic priorities by focusing on differentiated products and maintaining cost discipline. During the first nine months of 2026, ADAMA successfully launched 31 new products and secured 70 new registrations. Key global product introductions included REXARO® and ACTAGON™ in India, RAVARI® in Mexico, and PORAFAM® Titan kit in Germany.

Leadership Transition and Outlook

ADAMA announced that CEO Gaël Hili will step down in November 2026 to transition into the role of Chairman of the Board. Dr. Zhigang Hao is slated to assume leadership to continue the company's strategic initiatives. Despite regional geopolitical tensions, the company confirmed that its production facilities in Israel remain operational. Investors can review the detailed financial appendix and the full results filing via the ADAMA investor relations portal or through the Shenzhen Stock Exchange (SZSE) disclosures.